Aceclofenac

Evidence Level: L5

Predicted Indications: 7

Aceclofenac

Pharmacist Assessment Report

Aceclofenac: From Rheumatoid Arthritis and Osteoarthritis to Brachyolmia-Amelogenesis Imperfecta Syndrome

One-Sentence Summary

Aceclofenac is an oral NSAID originally used to relieve pain and inflammation in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. The TxGNN model ranks brachyolmia-amelogenesis imperfecta syndrome as its top prediction, but there are 0 clinical trials and 0 publications supporting it, so it is a model prediction only.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, arthropathy, frozen shoulder (the license records in the data compiled for this report contain no approved indication text)
Predicted New Indication	Brachyolmia-amelogenesis imperfecta syndrome
TxGNN Prediction Score	0.9989
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for this report. Aceclofenac is a phenylacetic acid-derivative NSAID, related to diclofenac. The literature describes it as having analgesic and anti-inflammatory effects, mainly through prostaglandin inhibition. Its efficacy in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis is well documented.

For the top-ranked prediction, a plausible mechanistic link is hard to find. Brachyolmia-amelogenesis imperfecta syndrome is a rare genetic skeletal and dental developmental disorder. An NSAID would not be expected to alter its underlying pathology. The same holds for the next few predictions (acromesomelic dysplasia Hunter-Thompson type, brachyolmia, pseudoachondroplasia). These are genetic skeletal dysplasias, and the high scores come from the TxGNN model (deep learning) and most likely reflect similarities the model learned between related diseases, not biological evidence or a real pharmacological relationship.

Hypermobility of coccyx and myosclerosis have only class-level or speculative links. Kummell disease would at most receive analgesia.

Clinical Trial Evidence

Currently no related clinical trials registered for the top-ranked prediction, or for any of the other nine predictions.

Literature Evidence

Currently no related literature is available for the top-ranked prediction.

PMID	Year	Type	Journal	Key Findings
8823693	1996	Clinical study (controlled, multicenter)	J Rheumatol	Efficacy and tolerability of aceclofenac vs indomethacin in active ankylosing spondylitis
8823692	1996	Comparative clinical study	J Rheumatol	3-month multicenter comparison of aceclofenac 100 mg twice daily vs tenoxicam in ankylosing spondylitis; reported as safe and effective
34876850	2021	Review	J Pain Res	Analgesic and anti-inflammatory effects of aceclofenac in musculoskeletal disorders (low back pain, OA, RA, AS)
15163279	2004	Review	Expert Opin Pharmacother	Aceclofenac as effective as diclofenac, naproxen and piroxicam in OA, and as comparator NSAIDs in RA and AS
11511027	2001	Review	Drugs	Symptomatic relief of pain and joint inflammation in rheumatic disease, similar to other NSAIDs
8799688	1996	Review	Drugs	Pharmacology and therapeutic potential; efficacy similar to diclofenac and indomethacin, with preclinical suggestion of less gastrointestinal damage
11523298	2001	Review	Rev Med Liege	Role of aceclofenac in chronic osteoarthritis, including effects on cartilage remodeling
10081315	1999	Review/drug profile	Rev Med Liege	Indicated for symptomatic treatment of pain and inflammatory or degenerative arthropathies; usual dose 100 mg twice daily

India Market Information

Aceclofenac has 20 valid single-ingredient registrations in India. The records contain no approved indication text. Five representative authorizations:

Authorization Number	Product Name	Dosage Form	Approved Indication
Registration No. 76207	Eenac-SP Tablet	Strip of 10 tablets	Not stated in the compiled records
Registration No. 37081	Ceknac Plus Tablet	Strip of 10 tablets	Not stated in the compiled records
Registration No. 194444	Riofenac-P Oral Suspension	Bottle of 60 ml oral suspension	Not stated in the compiled records
Registration No. 106002	Hilnac-SR Tablet	Strip of 10 sustained-release tablets	Not stated in the compiled records
Registration No. 8938	Abate 200mg Tablet SR	Strip of 10 sustained-release tablets	Not stated in the compiled records

All products are oral (tablets, sustained-release tablets and oral suspension).

Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications or drug interaction records were available in the data compiled for this report.

One literature item is a case report of generalized pustular psoriasis precipitated by aceclofenac (PMID 16922973, 2006), which indicates a rare cutaneous adverse reaction. Any use in children (for example, juvenile arthritis) would need a separate pediatric safety evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction, brachyolmia-amelogenesis imperfecta syndrome, rests on a score from the TxGNN model (deep learning) alone, which may reflect similarities the model learned between related diseases, not biological evidence. There are no trials or publications, and no plausible mechanistic link between an NSAID and a genetic skeletal and dental developmental disorder. The nine other top predictions are similarly unsupported, so none represents a validated new repurposing opportunity.

To proceed, the following is needed:

Package insert warnings and contraindications for the Indian products (blocking for any safety screening)
Mechanism of action data for aceclofenac
Any preclinical or clinical evidence linking aceclofenac to a predicted indication, which does not exist in the data compiled for this report
Pediatric safety data if juvenile arthritis is pursued
Route compatibility and similarity-to-original-indication assessments, which are still pending
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.